Author Index

Allen, L.B., see Teepe, A.G., 227
Ambrose, M.W., see Wyde, P.R., 215
Ambrose, M.W., see Wyde, P.R., 237
Andrei, G. and De Clercq, E., Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro, 287
Anisimová, E., see Vonka, V., 117
Arai, Y.T., see Yamamoto, K., 173
Ashida, N., see Machida, H., 99

Balogh, K., see Kreider, J.W., 51
Balzarini, J., see Puech, F., 11
Balzarini, J., see Van Aerschot, A., 357
Baratta, D., see Garozzo, A., 267
Barrow, G.I., see Higgins, P.G., 3
Barrow, G.I., see Higgins, P.G., 339
Benveniste, R.E., see Tsai, C.-C., 87
Blaton, N., see Van Aerschot, A., 357
Brown, S., see Garcon, N.M., 109
Buimovici-Klein, E., Mohan, V., Lange, M., Fenamore, E., Inada, Y. and Cooper, L.Z., Inhibition of HIV replication in lymphocyte cultures of virus-positive subjects in the presence of Sho-saiko-to, an oriental plant extract, 279

Castro, A., see Garozzo, A., 267
Cerny, J., see Vonka, V., 117
Chou, T.C., see Yang, Z.H., 249
Cooper, L.Z., see Buimovici-Klein, E., 279
Crouch, J.Y., see Yang, Z.H., 249
Curley, D., McGuigan, C., Devine, K.G., O'Connor, T.J., Jeffries, D.J. and Kinchington, D., Synthesis and anti-HIV evaluation of some phosphoramidate derivatives of AZT: studies on the effect of chain elongation on biological activity, 345
Czelusniak, S.M., see Klein, R.J., 207

De Clercq, E., see Andrei, G., 287
De Clercq, E., see Puech, F., 11
De Clercq, E., see Van Aerschot, A., 357
De Ranter, C., see Van Aerschot, A., 357
Deaver, L.E., see Tsai, C.-C., 87
Devine, K.G., see Curley, D., 345

Everaert, D., see Van Aerschot, A., 357

Fenamore, E., see Buimovici-Klein, E., 279
Feng, J.S., see Yang, Z.H., 249
Follis, K.E., see Tsai, C.-C., 87
Freeman, D.J., see Spruance, S.L., 305
Freeman, J., see Kreis, W., 323
Furneri, P.M., see Garozzo, A., 267

Garcon, N.M., Groothuis, J., Brown, S., Lauer, B., Pietrobon, P. and Six, H.R., Serum IgG subclass antibody responses in children vaccinated with influenza virus antigens by live attenuated or inactivated vaccines, 109
Garozzo, A., Pinizzotto, M.R., Furneri, P.M., Baratta, D., Guerrera, F., Castro, A., Tornetta, B. and Geremia, E., Inhibitory effects of 3-imino-5-phenyl-3H-1,2-dithiole on poliovirus type 1 replication in vitro, 267
Gauci, G.L., see Higgins, P.G., 3
Geremia, E., see Garozzo, A., 267
Gilbert, B.E., see Wyde, P.R., 215
Gilbert, B.E., see Wyde, P.R., 237
Glück, R., see Lüscher-Mattli, M., 39
Good, S.S., see Puech, F., 11
Gosselin, G., see Puech, F., 11
Gosselin, G., see Van Aerschot, A., 357
Groothuis, J., see Garcon, N.M., 109
Guerrera, F., see Garozzo, A., 267

Hansen, J.-E.S., Witzke, N.M., Nielsen, C., Mathiesen, L.R., Teglbjaerg, L.S., Nielsen, C.M. and Nielsen, J.O., Derivatives of amphotericin infection with human immunodeficiency virus in vitro by different modes of action, 149
Harris, E.F., see Teepe, A.G., 227
Hasobe, M., see Yamamoto, K., 173
Hay, A.J., see Hayden, F.G., 25
Hayden, F.G., Rollins, B.S. and Hay, A.J., Anti-influenza virus activity of the compound LY25396, 25
Helsberg, M., see Winkler, I., 61
Herdewijn, P., see Van Aerschot, A., 357
Higgins, P.G., Barrow, G.I. and Tyrrell, D.A.J., A study of the efficacy of the bradykinin antagonist, NPC 567, in rhinovirus infections in human volunteers, 339
Higgins, P.G., Barrow, G.I., Tyrrell, D.A.J., Isaacs, D. and Gauci, G.L., The efficacy of intranasal interferon 2-a in respiratory syncytical virus infection in volunteers, 3
Holy, A., see Vonka, V., 117
Hsiung, G.D., see Yang, Z.H., 249

Ickes, D.E., Venetta, T.M., Phonphok, Y. and Rosenthal, K.S., Tromantadine inhibits a late step in herpes simplex virus type 1 replication and syncytium formation, 75
Ikeda, T., see Machida, H., 99
Imbach, J.-L., see Puech, F., 11
Imbach, J.-L., see Van Aerschot, A., 357
Inada, Y., see Buimovici-Klein, E., 279
Isaacs, D., see Higgins, P.G., 3

Jeffries, D.J., see Curley, D., 345
Jähne, G., see Winkler, I., 61

Kaplan, M.H., see Kreis, W., 323
Khyatti, M. and Menezes, J., The effect of indometacin, prostaglandin E2 and interferon on the multiplication of herpes simplex virus type 1 in human lymphoid cells, 161
Kinchington, D., see Curley, D., 345
Kitano, T., see Yamamoto, K., 173
Klein, R.J. and Czelusniak, S.M., Effect of a thymidine kinase inhibitor L-653,180) on antiviral treatment of experimental herpes simplex virus infection in mice, 207
Kreider, J.W., Balogh, K., Olson, R.O. and Martin, J.C., Treatment of latent rabbit and human papillomavirus infections with 9-(2-phosphonylmethoxy)ethylguanine (PMEG) (Short Communication), 51
Kreis, W., Kaplan, M.H., Freeman, J., Sun, D.K. and Sarin, P.S., Inhibition of HIV replication by *Hyssop officinalis* extracts, 323

Lange, M., see Buimovici-Klein, E., 279
Lauer, B., see Garcon, N.M., 109
Litterst, C., see Nasr, M., 125
Lüscher-Mattli, M. and Glück, R., Dextran sulfate inhibits the fusion of influenza virus with model membranes, and suppresses influenza virus replication in vivo, 39

Machida, H., Ikeda, T. and Ashida, N., Comparison of antiviral efficacies of 1- -D-arabinofuranosyl-E-5-(2-bromovinyl) uracil (brovavir) and acyclovir against herpes simplex virus type 1 infections in mice, 99
Martin, J.C., see Kreider, J.W., 51
Mathiesen, L.R., see Hansen, J.-E.S., 149
McGowan, J., see Nasr, M., 125
McGuigan, C., see Curley, D., 345
Menezes, J., see Khyatti, M., 161
Meyer, H.L., see Wyde, P.R., 215
Meyer, H.L., see Wyde, P.R., 237
Mohan, V., see Buimovici-Klein, E., 279

Nasr, M., Litterst, C. and McGowan, J., Computer-assisted structure-activity correlations of dideoxynucleoside analogs as potential anti-HIV drugs, 125
Nielsen, C., see Hansen, J.-E.S., 149
Nielsen, C.M., see Hansen, J.-E.S., 149
Nielsen, J.O., see Hansen, J.-E.S., 149

O'Connor, T.J., see Curley, D., 345
Olson, R.O., see Kreider, J.W., 51

Peeters, O., see Van Aerschot, A., 357
Phonphok, Y., see Ickes, D.E., 75
Pietrobon, P., see Garcon, N.M., 109
Pinizzotto, M.R., see Garozzo, A., 267
Prichard, M.N. and Shipman Jr., C., A Three-dimensional model to analyze drug-drug interactions, 181
Puech, F., Gosselin, G., Balzarini, J., Good, S.S., Rideout, J.L., De Clercq, E. and Imbach, J.-L., Synthesis and biological evaluation of dinucleoside methylphosphonates of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxycytidine, 11

Rideout, J.L., see Puech, F., 11
Rollins, B.S., see Hayden, F.G., 25
Rosenberg, I., see Vonka, V., 117
Rosenthal, K.S., see Ickes, D.E., 75
Rösner, M., see Winkler, I., 61

Sager, P.R., see Tsai, C.-C., 87
Saneyoshi, M., see Yamamoto, K., 173
Sarin, P.S., see Kreis, W., 323
Scholl, T., see Winkler, I., 61
Shipman Jr., C., see Prichard, M.N., 181
Six, H.R., see Garcon, N.M., 109
Spruance, S.L. and Freeman, D.J., Topical treatment of cutaneous herpes simplex virus infections, 305
Sun, D.K., see Kreis, W., 323

Teepe, A.G., Allen, L.B., Wordinger, R.J. and Harris, E.F., Effect of the extrous cycle on susceptibility of female mice to intravaginal inoculation of herpes simplex virus type 2 (HSV-2), 227
Teglbjaerg, L.S., see Hansen, J.-E.S., 149
Tornetta, B., see Garozzo, A., 267
Tsai, C.-C., Follis, K.E., Yarnall, M., Deaver, L.E., Benveniste, R.E. and Sager, P.R., In vitro screening for antiretroviral agents against simian immunodeficiency virus (SIV), 87
Tyrrell, D.A.J., see Higgins, P.G., 3
Tyrrell, D.A.J., see Higgins, P.G., 339

Van Aerschot, A., Everaert, D., Gosselin, G., Peeters, O., Blaton, N., De Ranter, C., Imbach, J.-L., Balzarini, J., De Clercq, E. and Herdewijn, P., 2′-Azido-2′,3′-dideoxythymidine: synthesis and crystal structure of a 2′-substituted dideoxynucleoside, 357
Venetta, T.M., see Ickes, D.E., 75
Vonka, V., Anisimová, E., Cerny, J., Holy, A., Rosenberg, I. and Votruba, I., Properties of a 9-(2-phosphonylmethoxyethyl)adenine (PMEA)-resistant herpes simplex virus type 1 virus mutant (Short Communication), 117
Votruba, I., see Vonka, V., 117

Winkelmann, E., see Winkler, I., 61
Winkler, I., Winkelmann, E., Scholl, T., Rösner, M., Jähne, G. and Helsberg, M., Antiviral activity and pharmacokinetics of HOE 602, an acyclic nucleoside, in animal models, 61
Witzke, N.M., see Hansen, J.-E.S., 149
Wordinger, R.J., see Teepe, A.G., 227
Wyde, P.R., Ambrose, M.W., Meyer, H.L. and Gilbert, B.E., Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats, 237
Wyde, P.R., Ambrose, M.W., Meyer, H.L., Zolinski, C.L. and Gilbert, B.E., Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats, 215

Yamamoto, K., Kitano, T., Arai, Y.T., Yoshii, K., Hasobe, M. and Saneyoshi, M., Inhibitory effect of a new antibiotic, guanine 7-N-oxide, on the replication of several RNA viruses, 173
Yang, Z.H., Crouch, J.Y., Feng, J.S., Chou, T.C. and Hsiung, G.D., Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro, 249
Yarnall, M., see Tsai, C.-C., 87
Yoshii, K., see Yamamoto, K., 173

Zolinski, C.L., see Wyde, P.R., 215

Subject Index

AIDS, Dideoxynucleoside 2′-substituted, 2′-AZT, Activity anti-HIV, Solid state conformation, 357

2′-AZT, Dideoxynucleoside 2′-substituted, Activity anti-HIV, AIDS, Solid state conformation, 357

AZT, HIV, Phosphoramidate derivative, 345

Acquired immunodeficiency syndrome, SIV, Antiretroviral agent, 87

Activity anti-HIV, Dideoxynucleoside 2′-substituted, 2′-AZT, AIDS, Solid state conformation, 357

Acyclic nucleotide, Human papillomavirus type 11, Cottontail rabbit papillomavirus, Athymic mouse, Domestic rabbit, PMEG, 51

Acyclovir, Brovavir, Encephalitis, Model infection, 99

Acyclovir, Herpes simplex virus, Thymidine kinase inhibitor, Experimental treatment, 207

Amphotericin B, HIV, Syncytium formation, 149

Animal model, Ganciclovir, HOE 602, Herpesvirus, Cytomegalovirus, 61

Anti-HIV activity, Hyssop Officinalis, Caffeic acid, 323

Anti-HIV drug, Dideoxynucleoside analog, Structure-activity correlation, Rational drug design, 125

Anti-RNA virus activity, Guanine 7-N-oxide, 173

Antiretroviral agent, SIV, Acquired immunodeficiency syndrome, 87

Antiviral activity, 3-Imino-5-phenyl-3H-1,2-dithiole poliovirus type 1, 267

Antiviral therapy, Herpes simplex virus, Topical drug formulation, Clinical trial, 305

Arenavirus, Nucleoside analoque, Sulfated polysaccharide, 287

Athymic mouse, Human papillomavirus type 11, Cottontail rabbit papillomavirus, Domestic rabbit, Acyclic nucleotide, PMEG, 51

Bradykinin antagonist (NPC 567), Rhinovirus, Human volunteer, 339

Brovavir, Acyclovir, Encephalitis, Model infection, 99

Caffeic acid, Hyssop Officinalis, Anti-HIV activity, 323

Carbocyclic 3-deazaadenosine, Respiratory syncytial virus, Parainfluenza virus type 3, Cotton rat, 215

Chemotherapy, Drug interaction, Three-dimensional, Synergy, 181

Clinical trial, Herpes simplex virus, Topical drug formulation, Antiviral therapy, 305

Combined antiviral effect, Guinea pig cytomegalovirus, Nucleoside, Dose-effect analysis, 249

Cotton rat, Respiratory syncytial virus, Parainfluenza virus type 3, Carbocyclic 3-deazaadenosine, 215

Cotton rat, LY253963, Respiratory syncytial virus, Parainfluenza virus, 237

Cottontail rabbit papillomavirus, Human papillomavirus type 11, Athymic mouse, Domestic rabbit, Acyclic nucleotide, PMEG, 51

Cytomegalovirus, Ganciclovir, HOE 602, Herpesvirus, Animal model, 61

Cytotoxicity, Influenza virus inhibition, LY253963, Ribavirin, Rimantadine, 25

Dextran sulfate, Influenza virus, Liposome, Fluorescence spectroscopy, Membrane fusion, 39

Dideoxynucleoside analog, Anti-HIV drug, Structure-activity correlation, Rational drug design, 125

Dideoxynucleoside 2′-substituted, 2′-AZT, Activity anti-HIV, AIDS, Solid state conformation, 357

Domestic rabbit, Human papillomavirus type 11, Cottontail rabbit papillomavirus, Athymic mouse, Acyclic nucleotide, PMEG, 51

Dose-effect analysis, Combined antiviral effect, Guinea pig cytomegalovirus, Nucleoside, 249

Drug interaction, Three-dimensional, Chemotherapy, Synergy, 181

Drug-resistant mutant, Herpes simplex virus, PMEA, 9-(2-Phosphonylmethoxythyl)adenine, 117

Encephalitis, Brovavir, Acyclovir, Model infection, 99

Estrous cycle, Herpes simplex virus, Vaginal inoculation, 227

Experimental treatment, Herpes simplex virus, Thymidine kinase inhibitor, Acyclovir, 207

Fluorescence spectroscopy, Dextran sulfate, Influenza virus, Liposome, Membrane fusion, 39

Fusion, Tromantadine, HSV-1, Syncytium formation, 75

Ganciclovir, HOE 602, Herpesvirus, Cytomegalovirus, Animal model, 61
Guanine 7-N-oxide, Anti-RNA virus activity, 173
Guinea pig cytomegalovirus, Combined antiviral effect, Nucleoside, Dose-effect analysis, 249

HIV, Amphotericin B, Syncytium formation, 149
HIV, Oriental plant extract, Inhibition, Reverse transcriptase, p24, 279
HIV, Phosphoramidate derivative, AZT, 345
HOE 602, Ganciclovir, Herpesvirus, Cytomegalovirus, Animal model, 61
HSV-1, Tromantadine, Syncytium formation, Fusion, 75
Herpes simplex virus, PMEA, 9-(2-Phosphonylmethoxythyl)adenine, Drug-resistant mutant, 117
Herpes simplex virus, Thymidine kinase inhibitor, Acyclovir, Experimental treatment, 207
Herpes simplex virus, Estrous cycle, Vaginal inoculation, 227
Herpes simplex virus, Topical drug formulation, Clinical trial, Antiviral therapy, 305
Herpesvirus, Ganciclovir, HOE 602, Cytomegalovirus, Animal model, 61
Human immunodeficiency virus, *O,O'*-bis(3'-azido-3'-deoxythymidin-5'-yl)methylphosphonate, *O,O'*-bis(2',3'-dideoxycytidin-5'-yl)methylphosphonate, 11
Human papillomavirus type 11, Cottontail rabbit papillomavirus, Athymic mouse, Domestic rabbit, Acyclic nucleotide, PMEG, 51
Human volunteer, Rhinovirus, Bradykinin antagonist (NPC 567), 339
Hyssop Officinalis, Caffeic acid, Anti-HIV activity, 323

3-Imino-5-phenyl-3H-1,2-dithiole poliovirus type 1, Antiviral activity, 267
Indometacin, Prostaglandin E2, Interferon, Multiplication of HSV-1, 161
Influenza virus inhibition, LY253963, Ribavirin, Rimantadine, Cytotoxicity, 25
Influenza virus, Dextran sulfate, Liposome, Fluorescence spectroscopy, Membrane fusion, 39
Influenza virus, Serum IgG, 109
Inhibition, HIV, Oriental plant extract, Reverse transcriptase, p24, 279
Interferon α-2a, RSV infection, Prophylaxis, Therapy, 3
Interferon, Indometacin, Prostaglandin E2, Multiplication of HSV-1, 161
LY253963, Influenza virus inhibition, Ribavirin, Rimantadine, Cytotoxicity, 25
LY253963, Respiratory syncytial virus, Parainfluenza virus, Cotton rat, 237
Liposome, Dextran sulfate, Influenza virus, Fluorescence spectroscopy, Membrane fusion, 39

Membrane fusion, Dextran sulfate, Influenza virus, Liposome, Fluorescence spectroscopy, 39
Model infection, Brovavir, Acyclovir, Encephalitis, 99
Multiplication of HSV-1, Indometacin, Prostaglandin E2, Interferon, 161

Nucleoside, Combined antiviral effect, Guinea pig cytomegalovirus, Dose-effect analysis, 249
Nucleoside analoque, Arenavirus, Sulfated polysaccharide, 287

O,O'-bis(3'-azido-3'-deoxythymidin-5'-yl)methylphosphonate, Human immunodeficiency virus, 11
O,O'-bis(2',3'-dideoxycytidin-5'-yl)methylphosphonate, Human immunodeficiency virus, 11
Oriental plant extract, HIV, Inhibition, Reverse transcriptase, p24, 279

p24, HIV, Oriental plant extract, Inhibition, Reverse transcriptase, 279
PMEA, Herpes simplex virus, 9-(2-Phosphonylmethoxythyl)adenine, Drug-resistant mutant, 117
PMEG, Human papillomavirus type 11, Cottontail rabbit papillomavirus, Athymic mouse, Domestic rabbit, Acyclic nucleotide, 51
Parainfluenza virus type 3, Respiratory syncytial virus, Carbocyclic 3-deazaadenosine, Cotton rat, 215
Parainfluenza virus, LY253963, Respiratory syncytial virus, Cotton rat, 237
9-(2-Phosphonylmethoxythyl)adenine, Herpes simplex virus, PMEA, Drug-resistant mutant, 117
Phosphoramidate derivative, HIV, AZT, 345
Prophylaxis, Interferon α-2a, RSV infection, Therapy, 3
Prostaglandin E2, Indometacin, Interferon, Multiplication of HSV-1, 161

RSV infection, Interferon 2a, Prophylaxis, Therapy, 3

Rational drug design, Dideoxynucleoside analog, Anti-HIV drug, Structure-activity correlation, 125
Respiratory syncytial virus, Parainfluenza virus type 3, Carbocyclic 3-deazaadenosine, Cotton rat, 215
Respiratory syncytial virus, LY253963, Parainfluenza virus, Cotton rat, 237
Reverse transcriptase, HIV, Oriental plant extract, Inhibition, p24, 279
Rhinovirus, Bradykinin antagonist (NPC 567), Human volunteer, 339
Ribavirin, Influenza virus inhibition, LY253963, Rimantadine, Cytotoxicity, 25
Rimantadine, Influenza virus inhibition, LY253963, Ribavirin, Cytotoxicity, 25

SIV, Acquired immunodeficiency syndrome, Antiretroviral agent, 87
Serum IgG, Influenza virus, 109
Solid state conformation, Dideoxynucleoside 2′-substituted, 2′-AZT, Activity anti-HIV, AIDS, 357
Structure-activity correlation, Dideoxynucleoside analog, Anti-HIV drug, Rational drug design, 125
Sulfated polysaccharide, Arenavirus, Nucleoside analoque, 287
Syncytium formation, Tromantadine, HSV-1, Fusion, 75
Syncytium formation, HIV, Amphotericin B, 149
Synergy, Drug interaction, Three-dimensional, Chemotherapy, 181

Therapy, Interferon α-2a, RSV infection, Prophylaxis, 3
Three-dimensional, Drug interaction, Chemotherapy, Synergy, 181
Thymidine kinase inhibitor, Herpes simplex virus, Acyclovir, Experimental treatment, 207
Topical drug formulation, Herpes simplex virus, Clinical trial, Antiviral therapy, 305
Tromantadine, HSV-1, Syncytium formation, Fusion, 75

Vaginal inoculation, Herpes simplex virus, Estrous cycle, 227